Upregulation of SIRT4 and downregulation of Smad4 can potentially counteract lipid accumulation, inflammation, and fibrosis during NAFLD progression [34]. The gene discussed is SIRT4; the disease is metabolic dysfunction-associated steatotic liver disease.